SCHEMBL3562545

SCHEMBL3562545

CC(C)(C)OC(=O)N1CCN(CCNc2ccnc3oc(-c4ccc(O)cc4)c(-c4ccccc4)c23)CC1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LCK P06239 16/20 0.60
TNK2 Q07912 16/20 0.60
KDR P35968 12/20 0.60
JAK3 P52333 11/20 0.60
KDM4E B2RXH2 1/20 0.44
AURKA O14965 1/20 0.44
USP2 O75604 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ACKR3 P25106 2/20 0.43
EGFR P00533 1/20 0.41
SRC P12931 1/20 0.41
ZAP70 P43403 1/20 0.41
ACHE P22303 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3563331 0.88 TNK2 (0.72) LCKTNK2KDRJAK3KDM4E
SCHEMBL3566530 0.87 TNK2 (0.74) LCKTNK2KDRJAK3KDM4E
SCHEMBL3562598 0.86 LCK (0.53) LCKTNK2KDRJAK3KDM4E
SCHEMBL3580014 0.84 LCK (0.57) LCKTNK2KDRJAK3EGFR
SCHEMBL3566646 0.84 LCK (0.41) LCKTNK2KDRJAK3KDM4E
SCHEMBL2968870 0.83 AURKA (0.66) LCKTNK2KDRJAK3KDM4E
SCHEMBL13202608 0.79 KDM4E (0.58) LCKTNK2KDRJAK3KDM4E
SCHEMBL2968690 0.79 TNK2 (0.60) LCKTNK2KDRJAK3KDM4E
SCHEMBL5358139 0.78 LCK (0.61) LCKTNK2KDRJAK3KDM4E
SCHEMBL2962332 0.78 TNK2 (0.60) LCKTNK2KDRJAK3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
EP-1791845-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2007-06-06 EP disclosed
WO-2006130160-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2006-12-07 WO disclosed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 LCK 1/4885TNK2 22/4885KDR 2629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.